In recent years, several new agents, such as glucagon-like peptide 1 (GLP1) analogs, dipeptidyl peptidase-4 (DPP4) inhibitors, and selective sodium-glucose cotransporter 2 (SGLT2) inhibitors, were introduced for T2DM treatment, mostly as an add-on to first-line treatment. The gene discussed is GCG; the disease is type 2 diabetes mellitus.